KR102006527B1 - 전립선-연관 항원의 발현을 위한 벡터 - Google Patents
전립선-연관 항원의 발현을 위한 벡터 Download PDFInfo
- Publication number
- KR102006527B1 KR102006527B1 KR1020167014145A KR20167014145A KR102006527B1 KR 102006527 B1 KR102006527 B1 KR 102006527B1 KR 1020167014145 A KR1020167014145 A KR 1020167014145A KR 20167014145 A KR20167014145 A KR 20167014145A KR 102006527 B1 KR102006527 B1 KR 102006527B1
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- leu
- gly
- nucleotide sequence
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001194—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
- C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21077—Semenogelase (3.4.21.77), i.e. prostate specific antigen or PSA or kallikrein 3
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
도 2. 5개의 바이러스 2A 카세트의 아미노산 정렬. 생략된 글라이신-프롤린 결합은 별표로 표시한다.
도 3. 바람직한 EMCV IRES의 서열. 번역 개시 부위는 별표로 표시한다. 최소 IRES 요소는 EMCV L 단백질의 밑줄친 처음 5개의 코돈을 제외한다.
도 4. 피하 TUBO 종양 보유 BALB/neuT 마우스에서 암 백신 (백신)의 항-종양 효능에 대한 수니티닙 말레이트 (수텐트) 및 항-뮤린 CTLA-4 모노클로날 항체 (클론 9D9)의 효과를 평가하는 대표적인 연구로부터 마우스의 군의 카플란-마이어 (Kaplan-Meier) 생존 곡선을 보여주는 그래프.
도 5. 암 백신 (rHER2)에 의해 유도된 항원 특이적 T 세포 반응에 대한 CpG7909 및 항-CD40 항체 (바이옥셀 (Bioxcell) #BE0016-2)의 효과를 평가하는 IFNγ ELISPOT 결과를 보여주는 그래프.
도 6. 시토카인 양성 CD8 T 세포를 측정하는 세포내 시토카인 염색 검정을 사용하여 암 백신 (PMED)에 의해 유도된 면역 반응의 품질에 대한 CpG7909의 면역조절 활성을 평가하는 대표적인 연구의 결과를 보여주는 그래프 (*는 스튜던트 T-시험 (Student's T-test)에 의한 P<0.05를 나타낸다).
도 7. 시토카인 양성 CD4 T 세포 (도 7)를 측정하는 세포내 시토카인 염색 검정을 사용하여 암 백신 (PMED)에 의해 유도된 면역 반응의 품질에 대한 CpG7909의 면역조절 활성을 평가하는 대표적인 연구의 결과를 보여주는 그래프 (*는 스튜던트 T-시험에 의한 P<0.05를 나타낸다).
도 8. 시토카인 양성 CD8 T 세포를 측정하는 세포내 시토카인 염색 검정을 사용하여 암 백신 (PMED)에 의해 유도된 면역 반응의 품질에 대한 효능제 항-뮤린 CD40 모노클로날 항체의 면역조절 활성을 평가하는 대표적인 연구의 결과를 보여주는 그래프 (*는 스튜던트 T-시험에 의한 P<0.05를 나타낸다).
도 9. 시토카인 양성 CD4 T 세포를 측정하는 세포내 시토카인 염색 검정을 사용하여 암 백신 (PMED)에 의해 유도된 면역 반응의 품질에 대한 효능제 항-뮤린 CD40 모노클로날 항체의 면역조절 활성을 평가하는 대표적인 연구의 결과를 보여주는 그래프 (*는 스튜던트 T-시험에 의한 P<0.05를 나타낸다).
도 10. 자발적 유방 종양 보유 BALB/neuT 마우스에서 암 백신의 항-종양 효능에 대한 저용량 수니티닙 말레이트 (수텐트)의 효과를 평가하는 대표적인 연구로부터 마우스의 군의 카플란-마이어 생존 곡선을 보여주는 그래프.
도 11. AdC68-734 벡터의 게놈 구성을 보여주는 그래프. CMV Enh/pro = 인간 사이토메갈로바이러스 최조기 (immediate early) 인핸서 및 프로모터; tet op = 테트라사이클린 작동유전자; T2A = 토세아 아시그나(Thosea asigna) 바이러스 2A; F2A = 구제역 바이러스 2A; SV40 pA = 원숭이 바이러스 40 폴리아데닐화 신호; LITR = 좌측 역위 말단 반복체; RITR = 우측 역위 말단 반복체.
도 12. 유동 세포 분석에 의해 삼중 항원 발현 AdC68 벡터로 형질도입된 A549 세포의 표면 상의 PSMA 및 PSCA의 발현을 보여주는 점 그래프.
도 13. AdC68 벡터에 의해 감염된 A549의 용해물에 대한 웨스턴 블롯 (Western blot).
Claims (24)
- (a) C68 뉴클레오티드 서열; 및
(b) 면역원성 PSA 폴리펩티드를 코딩하는 적어도 하나의 뉴클레오티드 서열, 면역원성 PSCA 폴리펩티드를 코딩하는 적어도 하나의 뉴클레오티드 서열, 및 면역원성 PSMA 폴리펩티드를 코딩하는 적어도 하나의 뉴클레오티드 서열을 포함하는 다중-항원 구축물을 포함하고,
여기서 면역원성 PSA 폴리펩티드는 서열 15의 아미노산 27-263 또는 서열 17의 아미노산 4-240을 포함하는 다중-항원 구축물을 포함하는 것이고,
면역원성 PSMA 폴리펩티드가
1) 서열 1의 아미노산 15-750을 포함하는 폴리펩티드;
2) 서열 3의 아미노산 서열을 포함하는 폴리펩티드;
3) 서열 5의 아미노산 서열을 포함하는 폴리펩티드;
4) 서열 7의 아미노산 서열을 포함하는 폴리펩티드;
5) 서열 9의 아미노산 4-739를 포함하는 폴리펩티드;
6) 서열 3의 아미노산 4-739를 포함하는 폴리펩티드;
7) 서열 5의 아미노산 4-739를 포함하는 폴리펩티드;
8) 서열 7의 아미노산 4-739를 포함하는 폴리펩티드; 및
9) 서열 9의 아미노산 서열을 포함하는 폴리펩티드
로 이루어진 군으로부터 선택되는 것인,
C68 벡터. - 제1항에 있어서, C68 뉴클레오티드 서열이 E1A, E1B, E2A, E2B, E3, E4, L1, L2, L3, L4 및 L5 유전자로 이루어진 군으로부터 선택되는 적어도 하나의 유전자가 결여된 서열 57의 서열이고, 면역원성 PSCA 폴리펩티드가 서열 21의 아미노산 서열 또는 서열 21의 아미노산 4-125를 포함하는 것이고, 면역원성 PSMA 폴리펩티드가 서열 1의 아미노산 15-750을 포함하는 것인 C68 벡터.
- 제1항에 있어서, C68 뉴클레오티드 서열이 E1A, E1B, 및 E3의 유전자가 결여된 서열 57의 서열이고, 다중-항원 구축물이 2개의 상이한 면역원성 폴리펩티드를 코딩하는 2개의 뉴클레오티드 서열 사이에 분리자 서열을 추가로 포함하고 하기 식 (I)의 구조를 갖는 것인 C68 벡터.
PAA1-SS1-PAA2-SS2-PAA3 (I)
식 (I)에서,
(i) PAA1, PAA2, 및 PAA3이 상이한 PAA 폴리펩티드를 코딩할 경우, PAA1, PAA2, 및 PAA3은 각각 면역원성 PSA 폴리펩티드를 코딩하는 뉴클레오티드 서열, 면역원성 PSCA 폴리펩티드를 코딩하는 뉴클레오티드 서열, 또는 면역원성 PSMA 폴리펩티드를 코딩하는 뉴클레오티드 서열이고,
(ii) SS1 및 SS2는 분리자 서열이며, 동일하거나 상이할 수 있다. - 제3항에 있어서, 분리자 서열이 2A 펩티드 서열 및 IRES로부터 선택되는 것인 C68 벡터.
- 제4항에 있어서, 2A 펩티드 서열이 FMDV, ERAV, PTV1, EMC-B, EMCV, TME-GD7, ERBV, TaV, DrosC, CrPV, ABPV, IFV, 돼지 로타바이러스, 인간 로타바이러스, 티. 브루세이(T. brucei) TSR1, 및 티. 크루지(T. cruzi) AP 엔도뉴클레아제의 2A-펩티드 서열로 이루어진 군으로부터 선택되고; IRES가 EMCV IRES인 C68 벡터.
- 제5항에 있어서, 식 (I)에서 PAA1이 면역원성 PSA 폴리펩티드를 코딩하는 뉴클레오티드 서열, 또는 면역원성 PSCA 폴리펩티드를 코딩하는 뉴클레오티드 서열인 C68 벡터.
- 제6항에 있어서,
(i) PAA1이 면역원성 PSA 폴리펩티드를 코딩하는 뉴클레오티드 서열이고;
(ii) PAA2가 면역원성 PSCA 또는 PSMA 폴리펩티드를 코딩하는 뉴클레오티드 서열이고;
(iii) SS1이 2A-펩티드 서열이고;
(iv) SS2가 2A-펩티드 서열 또는 EMCV IRES인 C68 벡터. - 제7항에 있어서, 2A-펩티드 서열이 FMDV 2A-펩티드 서열 또는 TAV 2A-펩티드 서열인 C68 벡터.
- 제1항에 있어서,
(1) 면역원성 PSA 폴리펩티드를 코딩하는 뉴클레오티드 서열이 (i) 서열 18의 뉴클레오티드 서열; (ii) 서열 20의 뉴클레오티드 서열; (iii) 서열 18의 뉴클레오티드 10-720을 포함하는 뉴클레오티드 서열; (iv) 서열 58의 뉴클레오티드 1115-1825를 포함하는 뉴클레오티드 서열; 및 (v) 서열 58의 뉴클레오티드 1106-1825를 포함하는 뉴클레오티드 서열로 이루어진 군으로부터 선택되고;
(2) 면역원성 PSCA 폴리펩티드를 코딩하는 뉴클레오티드 서열이 (i) 서열 22의 뉴클레오티드 서열; (ii) 서열 58의 뉴클레오티드 1892-2257을 포함하는 뉴클레오티드 서열; 및 (iii) 서열 58의 뉴클레오티드 1886-2257을 포함하는 뉴클레오티드 서열로 이루어진 군으로부터 선택되고;
(3) 면역원성 PSMA 폴리펩티드를 코딩하는 뉴클레오티드 서열이 (i) 서열 2의 뉴클레오티드 43-2250을 포함하는 뉴클레오티드 서열; (ii) 서열 4의 뉴클레오티드 서열; (iii) 서열 6의 뉴클레오티드 서열; (iv) 서열 8의 뉴클레오티드 서열; (v) 서열 10의 뉴클레오티드 서열; (vi) 서열 4의 뉴클레오티드 10-2217을 포함하는 뉴클레오티드 서열; (vii) 서열 6의 뉴클레오티드 10-2217을 포함하는 뉴클레오티드 서열; (viii) 서열 8의 뉴클레오티드 10-2217을 포함하는 뉴클레오티드 서열; (ix) 서열 10의 뉴클레오티드 10-2217을 포함하는 뉴클레오티드 서열; (x) 서열 58의 뉴클레오티드 2333-4543을 포함하는 뉴클레오티드 서열; 및 (xi) 서열 58의 뉴클레오티드 2324-4543을 포함하는 뉴클레오티드 서열로 이루어진 군으로부터 선택되는 것인 C68 벡터. - 제3항에 있어서, 식 (I)에서
(1) PAA1이 면역원성 PSA 폴리펩티드를 코딩하는 뉴클레오티드 서열이고, 서열 58의 뉴클레오티드 1115-1825를 포함하거나 서열 58의 1106-1825를 포함하고;
(2) PAA2가 면역원성 PSCA 폴리펩티드를 코딩하는 뉴클레오티드 서열이고, 서열 58의 뉴클레오티드 1892-2257을 포함하거나 서열 58의 1886-2257을 포함하고;
(3) PAA3이 면역원성 PSMA 폴리펩티드를 코딩하는 뉴클레오티드 서열이고, 서열 58의 뉴클레오티드 2333-4543을 포함하거나 서열 58의 2324-4543을 포함하고;
(4) SS1이 T2A를 코딩하는 뉴클레오티드 서열이고;
(5) SS2가 F2A를 코딩하는 뉴클레오티드 서열인 C68 벡터. - 제1항에 있어서, 다중-항원 구축물이 서열 60 또는 서열 64의 아미노산 서열을 코딩하는 뉴클레오티드 서열을 포함하는 것인 C68 벡터.
- 제1항에 있어서, 다중-항원 구축물이 서열 61, 서열 65, 또는 서열 66의 뉴클레오티드 서열, 또는 서열 61, 서열 65, 또는 서열 66의 뉴클레오티드 서열의 축중성 변이체를 포함하는 것인 C68 벡터.
- 제11항에 있어서, CMV 프로모터를 추가로 포함하는 C68 벡터.
- 제1항에 있어서, 서열 58의 뉴클레오티드 서열, 서열 58의 뉴클레오티드 9-34811, 또는 서열 63의 뉴클레오티드 서열을 포함하는 C68 벡터.
- 제1항 내지 제14항 중 어느 한 항에 따른 C68 벡터를 포함하고, 인간에서 전립선암의 치료를 위한 조성물.
- 제1항 내지 제14항 중 어느 한 항에 따른 C68 벡터를 포함하는 세포.
- 제1항 내지 제14항 중 어느 한 항에 따른 벡터 및 제약상 허용되는 부형제를 포함하고, 인간에서 전립선암의 치료를 위한 제약 조성물.
- 삭제
- 제17항에 있어서, 유효량의 면역 조절제를 추가로 포함하는 제약 조성물.
- 제17항에 있어서, (a) 유효량의 적어도 하나의 면역억제성-세포 억제제 및 (b) 유효량의 적어도 하나의 면역이펙터-세포 증강제를 추가로 포함하는 제약 조성물.
- 제20항에 있어서, 면역억제성-세포 억제제가 단백질 키나제 억제제, COX-2 억제제, 및 PDE5 억제제로 이루어진 군으로부터 선택되고, 면역이펙터-세포 증강제가 CTLA-4 억제제, CD40 효능제, TLR 효능제, 4-1BB 효능제, OX40 효능제, GITR 효능제, PD-1 길항제, 및 PD-L1 길항제로 이루어진 군으로부터 선택되는 것인 제약 조성물.
- 제21항에 있어서,
(1) 단백질 키나제 억제제가 이마티닙, 소라페닙, 라파티닙, 작티마, MP-412, 다사티닙, 레스타우르티닙, 수니티닙 말레이트, 악시티닙, 에를로티닙, 게피티닙, 보수티닙, 템시롤리스무스, 및 닐로티닙으로 이루어진 군으로부터 선택되고;
(2) CTLA-4 억제제가 이필리무맙 및 트레멜리무맙으로 이루어진 군으로부터 선택되고;
(3) CD40 효능제가 G28-5, mAb89, EA-5, S2C6, CP870893, 및 다세투주맙으로 이루어진 군으로부터 선택되는 항-CD40 항체이고;
(4) TLR 효능제가 CpG24555, CpG10103, CpG7909, 및 CpG1018로 이루어진 군으로부터 선택되는 CpG 올리고뉴클레오티드인 제약 조성물. - 제22항에 있어서, 면역억제성-세포 억제제가 소라페닙, 다사티닙, 이마티닙, 악시티닙, 및 수니티닙 말레이트로 이루어진 군으로부터 선택되는 단백질 키나제 억제제이고, 면역이펙터-세포 증강제가 트레멜리무맙인 제약 조성물.
- 제22항에 있어서, 면역억제성-세포 억제제가 소라페닙, 다사티닙, 이마티닙, 악시티닙, 및 수니티닙 말레이트로 이루어진 군으로부터 선택되는 단백질 키나제 억제제이고, 면역이펙터-세포 증강제가 CpG24555, CpG10103, CpG7909, 및 CpG1018로 이루어진 군으로부터 선택되는 CpG 올리고뉴클레오티드인 제약 조성물.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361898966P | 2013-11-01 | 2013-11-01 | |
| US61/898,966 | 2013-11-01 | ||
| PCT/IB2014/065419 WO2015063647A1 (en) | 2013-11-01 | 2014-10-17 | Vectors for expression of prostate-associated antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197021909A Division KR102196884B1 (ko) | 2013-11-01 | 2014-10-17 | 전립선-연관 항원의 발현을 위한 벡터 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160068974A KR20160068974A (ko) | 2016-06-15 |
| KR102006527B1 true KR102006527B1 (ko) | 2019-08-02 |
Family
ID=51945953
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197021909A Expired - Fee Related KR102196884B1 (ko) | 2013-11-01 | 2014-10-17 | 전립선-연관 항원의 발현을 위한 벡터 |
| KR1020167014145A Expired - Fee Related KR102006527B1 (ko) | 2013-11-01 | 2014-10-17 | 전립선-연관 항원의 발현을 위한 벡터 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197021909A Expired - Fee Related KR102196884B1 (ko) | 2013-11-01 | 2014-10-17 | 전립선-연관 항원의 발현을 위한 벡터 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9402901B2 (ko) |
| EP (2) | EP3524262A1 (ko) |
| JP (3) | JP2016535989A (ko) |
| KR (2) | KR102196884B1 (ko) |
| CN (1) | CN105682679B (ko) |
| AR (2) | AR098256A1 (ko) |
| AU (2) | AU2014343321B2 (ko) |
| BR (1) | BR112016008806A2 (ko) |
| CA (1) | CA2928908C (ko) |
| DK (1) | DK3062815T3 (ko) |
| ES (1) | ES2715890T3 (ko) |
| HU (1) | HUE043042T2 (ko) |
| IL (1) | IL244897A0 (ko) |
| MX (2) | MX2016005656A (ko) |
| MY (2) | MY196581A (ko) |
| NZ (1) | NZ718652A (ko) |
| PE (1) | PE20171142A1 (ko) |
| PH (2) | PH12016500673A1 (ko) |
| PL (1) | PL3062815T3 (ko) |
| PT (1) | PT3062815T (ko) |
| RU (2) | RU2650860C2 (ko) |
| SA (1) | SA516371030B1 (ko) |
| SG (2) | SG10201910889VA (ko) |
| SI (1) | SI3062815T1 (ko) |
| TR (1) | TR201903074T4 (ko) |
| TW (2) | TWI572717B (ko) |
| WO (1) | WO2015063647A1 (ko) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102196884B1 (ko) | 2013-11-01 | 2020-12-30 | 화이자 인코포레이티드 | 전립선-연관 항원의 발현을 위한 벡터 |
| EP3119893A1 (en) * | 2014-03-17 | 2017-01-25 | Taplmmune Inc. | Nucleic acid molecule vaccine compositions and uses thereof |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
| AU2016286091B2 (en) * | 2015-06-29 | 2021-02-04 | Verastem, Inc. | Therapeutic compositions, combinations, and methods of use |
| CA3008641A1 (en) | 2015-12-16 | 2017-06-22 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| ES2811523T3 (es) | 2016-01-19 | 2021-03-12 | Pfizer | Vacunas contra el cáncer |
| EP3408394B1 (en) * | 2016-01-27 | 2020-08-12 | Total Raffinage Chimie | Multigene expression in microalgae |
| EP3430148A4 (en) * | 2016-03-18 | 2020-01-01 | Nantcell, Inc. | MULTIMODAL VECTOR FOR DENDRITIC CELL INFECTION |
| CA3023022A1 (en) * | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| KR20190034503A (ko) * | 2016-06-03 | 2019-04-02 | 이투빅스 코포레이션 | 전립선암-연관 항원을 사용한 종양 백신접종을 위한 조성물 및 방법 |
| GB2549809C (en) * | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
| EP3522920A2 (en) * | 2016-10-10 | 2019-08-14 | Transgene SA | Immunotherapeutic product and mdsc modulator combination therapy |
| CN110545810A (zh) * | 2016-11-23 | 2019-12-06 | 磨石肿瘤生物技术公司 | 新抗原的病毒递送 |
| WO2018170238A2 (en) | 2017-03-15 | 2018-09-20 | Novavax, Inc. | Methods and compositions for inducing immune responses against clostridium difficile |
| PE20191842A1 (es) | 2017-05-08 | 2019-12-31 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus |
| AU2018300295A1 (en) | 2017-07-11 | 2020-01-23 | Pfizer Inc. | Immunogenic compositions comprising CEA MUC1 and TERT |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| KR102905054B1 (ko) | 2017-11-22 | 2025-12-29 | 시애틀 프로젝트 코포레이션 | 신생항원에 대한 접합 에피토프 제시 감소 |
| US20220153871A1 (en) | 2018-01-04 | 2022-05-19 | Iconic Therapeutics, Inc. | Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| TW202523847A (zh) * | 2019-05-30 | 2025-06-16 | 美商磨石生物公司 | 經修飾之腺病毒 |
| WO2021092095A1 (en) * | 2019-11-04 | 2021-05-14 | Gritstone Oncology, Inc. | Neoantigen vaccine therapy |
| RU2726541C1 (ru) * | 2019-11-19 | 2020-07-14 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | Рекомбинантная клеточная линия рака молочной железы человека BrCCh4e-134, экспрессирующая простат-специфический мембранный антиген человека |
| CN119264273A (zh) | 2019-12-03 | 2025-01-07 | 埃沃特克国际有限责任公司 | 干扰素相关抗原结合蛋白及其用途 |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| CN113088530A (zh) * | 2020-01-08 | 2021-07-09 | 怡道生物科技(苏州)有限公司 | 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法 |
| CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| CN119506295B (zh) * | 2025-01-21 | 2025-05-30 | 上海皓鸿生物医药科技有限公司 | 一种前列腺特异性膜抗原的制备方法 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US628371A (en) | 1898-09-10 | 1899-07-04 | Clark W Thomas | Machine for making berry-boxes. |
| US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
| ATE420171T1 (de) | 1994-07-15 | 2009-01-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| EP1039935A4 (en) | 1997-02-28 | 2005-04-27 | Univ Iowa Res Found | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| ATE441432T1 (de) | 1997-03-10 | 2009-09-15 | Ottawa Hospital Res Inst | Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien |
| ATE370740T1 (de) | 1997-05-20 | 2007-09-15 | Ottawa Health Research Inst | Verfahren zur herstellung von nukleinsäurekonstrukten |
| AU753172B2 (en) | 1997-06-06 | 2002-10-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| US6833438B1 (en) | 1999-06-01 | 2004-12-21 | Agensys, Inc. | Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| HRP20010551B1 (hr) | 1998-12-23 | 2013-05-31 | Pfizer Inc. | Humana monoklonalna antitijela za ctla-4 |
| WO2000049158A2 (en) | 1999-02-18 | 2000-08-24 | Compugen Ltd. | Psa and klk-2 splicing variants |
| CA2589418A1 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| AU6934600A (en) | 1999-08-27 | 2001-03-26 | Board Of Regents, The University Of Texas System | Cd40 ligand and cd40 agonist compositions and methods of use |
| CO5280092A1 (es) | 2000-02-15 | 2003-05-30 | Sugen Inc | Indolinas susutituidas con pirroles inhibidoras de proteinquinasas |
| AU5741001A (en) | 2000-04-28 | 2001-11-12 | Ctl Immunotherapies Corp | Epitope synchronization in antigen presenting cells |
| RU2192889C1 (ru) * | 2001-03-16 | 2002-11-20 | Эпштейн Олег Ильич | Лекарственное средство и способ лечения заболеваний предстательной железы |
| PT1857122E (pt) | 2001-06-05 | 2011-03-07 | Curevac Gmbh | Arnm estabilizado com teor de g/c aumentado, codificando para um antigénio viral |
| WO2003000283A1 (en) * | 2001-06-22 | 2003-01-03 | The Wistar Institute Of Anatomy And Biology | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
| EP1409748B1 (en) | 2001-06-22 | 2011-10-26 | The Trustees of The University of Pennsylvania | Recombinant Adenoviruses comprising simian adenovirus proteins and uses thereof. |
| CA2452119C (en) | 2001-07-05 | 2013-10-15 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
| US7211659B2 (en) * | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| JP4159988B2 (ja) | 2001-08-15 | 2008-10-01 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | N−[2−(ジエチルアミノ)エチル]−5−[(5−フルオロ−1,2−ジヒドロ−2−オキソ−3h−インドール−3−イリデン)メチル]−2,4−ジメチル−1h−ピロール−3−カルボキシアミドのリンゴ酸塩を含む結晶、その製法およびその組成物 |
| BR0206112A (pt) * | 2001-10-10 | 2005-05-10 | Centocor Inc | Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina |
| TWI228718B (en) | 2001-11-05 | 2005-03-01 | Tdk Corp | Manufacturing method and device of mold plate for information medium |
| CA2990322A1 (en) * | 2001-11-21 | 2003-06-05 | The Trustees Of The University Of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| RU2299209C2 (ru) | 2002-02-15 | 2007-05-20 | Фармация Энд Апджон Компани | Способ получения производных индолинона |
| HN2003000272A (es) | 2002-09-10 | 2008-07-29 | Pharmacia Italia Spa | Formulaciones que comprenden un compuesto de indolinona |
| CA2514419A1 (en) | 2003-01-28 | 2004-08-12 | Proscan Rx Pharma Inc. | Prostate cancer diagnosis and treatment |
| EP2319524B1 (en) | 2003-05-30 | 2013-08-21 | Agensys, Inc. | Prostate stem cell antigen (PSCA) variants and subsequences thereof |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| WO2005023765A1 (en) | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Method for catalyzing amidation reactions by the presence of co2 |
| GB0321615D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| EP1711518B1 (en) * | 2004-01-23 | 2009-11-18 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Chimpanzee adenovirus vaccine carriers |
| EP1742668B1 (en) | 2004-04-28 | 2011-02-09 | The Trustees of The University of Pennsylvania | Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations |
| DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
| BRPI0616090A2 (pt) | 2005-09-19 | 2011-06-07 | Veridex, Llc | métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida |
| NZ568016A (en) | 2005-12-07 | 2011-12-22 | Medarex Inc | CTLA-4 antibody dosage escalation regimens |
| WO2008010864A2 (en) | 2006-04-28 | 2008-01-24 | The Trustees Of The University Of Pennsylvania | Modified adenovirus hexon protein and uses thereof |
| GB0706914D0 (en) | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| KR20160065985A (ko) * | 2007-10-18 | 2016-06-09 | 버베리안 노딕 에이/에스 | 전립선 암 치료를 위한 mva의 용도 |
| IN2012DN02368A (ko) * | 2009-09-14 | 2015-08-21 | Baylor Res Insitute | |
| EP2638055B1 (en) * | 2010-11-12 | 2019-01-09 | The Trustees Of The University Of Pennsylvania | Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same |
| WO2012116714A1 (en) * | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| CA2832307A1 (en) * | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| CN102294025B (zh) * | 2011-08-10 | 2013-06-05 | 中国人民解放军第三军医大学第三附属医院 | 前列腺干细胞抗原多肽与核酸的复合物及其制备方法和应用 |
| SG10201603896RA (en) * | 2012-05-04 | 2016-07-28 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| KR102196884B1 (ko) * | 2013-11-01 | 2020-12-30 | 화이자 인코포레이티드 | 전립선-연관 항원의 발현을 위한 벡터 |
-
2014
- 2014-10-17 KR KR1020197021909A patent/KR102196884B1/ko not_active Expired - Fee Related
- 2014-10-17 CA CA2928908A patent/CA2928908C/en not_active Expired - Fee Related
- 2014-10-17 PL PL14802175T patent/PL3062815T3/pl unknown
- 2014-10-17 DK DK14802175.1T patent/DK3062815T3/en active
- 2014-10-17 AU AU2014343321A patent/AU2014343321B2/en not_active Ceased
- 2014-10-17 MY MYPI2020007026A patent/MY196581A/en unknown
- 2014-10-17 RU RU2016114416A patent/RU2650860C2/ru active
- 2014-10-17 JP JP2016526872A patent/JP2016535989A/ja active Pending
- 2014-10-17 NZ NZ718652A patent/NZ718652A/en not_active IP Right Cessation
- 2014-10-17 RU RU2018108259A patent/RU2018108259A/ru unknown
- 2014-10-17 PE PE2016000569A patent/PE20171142A1/es unknown
- 2014-10-17 EP EP18207060.7A patent/EP3524262A1/en not_active Withdrawn
- 2014-10-17 SG SG10201910889VA patent/SG10201910889VA/en unknown
- 2014-10-17 WO PCT/IB2014/065419 patent/WO2015063647A1/en not_active Ceased
- 2014-10-17 HU HUE14802175A patent/HUE043042T2/hu unknown
- 2014-10-17 TR TR2019/03074T patent/TR201903074T4/tr unknown
- 2014-10-17 MY MYPI2016701396A patent/MY182168A/en unknown
- 2014-10-17 CN CN201480059609.4A patent/CN105682679B/zh not_active Expired - Fee Related
- 2014-10-17 PT PT14802175T patent/PT3062815T/pt unknown
- 2014-10-17 KR KR1020167014145A patent/KR102006527B1/ko not_active Expired - Fee Related
- 2014-10-17 SG SG11201602625YA patent/SG11201602625YA/en unknown
- 2014-10-17 MX MX2016005656A patent/MX2016005656A/es active IP Right Grant
- 2014-10-17 EP EP14802175.1A patent/EP3062815B1/en not_active Not-in-force
- 2014-10-17 BR BR112016008806A patent/BR112016008806A2/pt not_active IP Right Cessation
- 2014-10-17 ES ES14802175T patent/ES2715890T3/es active Active
- 2014-10-17 SI SI201431100T patent/SI3062815T1/sl unknown
- 2014-10-29 TW TW103137445A patent/TWI572717B/zh not_active IP Right Cessation
- 2014-10-29 TW TW105139927A patent/TWI650418B/zh not_active IP Right Cessation
- 2014-10-29 US US14/527,226 patent/US9402901B2/en not_active Expired - Fee Related
- 2014-11-03 AR ARP140104090A patent/AR098256A1/es active IP Right Grant
-
2016
- 2016-04-04 IL IL244897A patent/IL244897A0/en unknown
- 2016-04-12 PH PH12016500673A patent/PH12016500673A1/en unknown
- 2016-04-28 SA SA516371030A patent/SA516371030B1/ar unknown
- 2016-04-29 MX MX2020001813A patent/MX2020001813A/es unknown
- 2016-05-04 US US15/146,578 patent/US10092636B2/en active Active
-
2018
- 2018-08-23 US US16/111,120 patent/US11173196B2/en not_active Expired - Fee Related
-
2019
- 2019-07-05 JP JP2019125723A patent/JP6621560B2/ja not_active Expired - Fee Related
- 2019-11-19 JP JP2019208986A patent/JP7014764B2/ja not_active Expired - Fee Related
-
2020
- 2020-03-25 AU AU2020202114A patent/AU2020202114A1/en not_active Abandoned
- 2020-04-17 AR ARP200101097A patent/AR118725A2/es unknown
- 2020-10-08 PH PH12020551666A patent/PH12020551666A1/en unknown
Non-Patent Citations (4)
| Title |
|---|
| Cancer Immunol Immunother. 2006 Dec* |
| Cancer Immunol Immunother. 55(12):1524-33 (2006.12.)* |
| J Gen Virol. 83(Pt 1):151-5 (2002.01.)* |
| Nat Rev Urol. 9(7):376-85 (2012.05.29.)* |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102006527B1 (ko) | 전립선-연관 항원의 발현을 위한 벡터 | |
| KR101728483B1 (ko) | 전립선 관련된 항원 및 백신 기재 면역치료 요법 | |
| AU2020260485B2 (en) | Gene therapies for lysosomal disorders | |
| KR20210150486A (ko) | 리소좀 장애에 대한 유전자 요법 | |
| EP4028033A1 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| CN111065408A (zh) | 免疫原性组合物 | |
| TW202233830A (zh) | 使用下一代工程化t細胞療法治療癌症之組合物及方法 | |
| HK40027086A (en) | Immunogenic compositions | |
| HK40048832A (en) | Gene therapies for lysosomal disorders | |
| HK40046514A (en) | Gene therapies for lysosomal disorders | |
| HK40048832B (zh) | 用於溶酶体障碍的基因疗法 | |
| KR20210150487A (ko) | 리소좀 장애를 위한 유전자 요법 | |
| HK40067825A (zh) | 用於溶酶体障碍的基因疗法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20220727 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20220727 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |